Eli Lilly Q3 2024 Adj EPS $1.18 Misses $1.45 Estimate, Sales $11.44B Miss $12.10B Estimate
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly's Q3 2024 earnings and sales missed analyst estimates, with EPS at $1.18 versus the expected $1.45, and sales at $11.44 billion versus the expected $12.10 billion. Despite the miss, both EPS and sales showed significant year-over-year growth.
October 30, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's Q3 2024 earnings per share of $1.18 missed the analyst estimate of $1.45, and sales of $11.44 billion missed the $12.10 billion estimate. Despite the miss, EPS increased by 1080% and sales by 20.43% year-over-year.
Eli Lilly's earnings and sales both missed analyst expectations, which is likely to negatively impact the stock price in the short term. However, the significant year-over-year growth in both EPS and sales may mitigate some of the negative sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100